{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:26:06Z","timestamp":1792700766675,"version":"4.5.0"},"reference-count":65,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2020,1,17]]},"abstract":"<jats:p>Checkpoint inhibitor therapy has shown tremendous efficacy, but also frequent and often severe side effects\u2014especially when multiple drugs of the class are used simultaneously. Similarly, many investigational immunotherapy agents, which have shown promise in animal models, have failed in clinical trials due to dose-limiting toxicity when administered systemically. This study utilized a murine melanoma model to evaluate the efficacy of intratumoral injections of recombinant NDVs engineered to express multiple immunotherapeutic proteins with well-documented side effects in humans. Our results indicate that intratumoral administration of these recombinant NDVs, particularly when combined with systemic CTLA4 checkpoint inhibition, exerts a robust effect in treated and nontreated tumors, indicative of a systemic antitumoral response. The intratumoral delivery of rNDVs expressing immunotherapeutic proteins may be an effective method of targeting the immune cell populations most relevant for antitumoral immunity and allowing us to restrict the use of systemic immunotherapy agents.<\/jats:p>","DOI":"10.1128\/jvi.01677-19","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T11:53:56Z","timestamp":1573127636000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":68,"title":["Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines"],"prefix":"10.1128","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8868-8265","authenticated-orcid":false,"given":"Gayathri","family":"Vijayakumar","sequence":"first","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McCroskery","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90071-X"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/85330"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.945"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.565"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021024"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.4110\/in.2014.14.6.265"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers3043856"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.8.622"},{"key":"e_1_3_2_22_2","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409\u2013417.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1025"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.181"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2008.04.020"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12391"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-1-131"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.12.4"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines7030066"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.747"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.3109\/08977194.2012.678843"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830270136"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9794-7_9"},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.4049\/jimmunol.161.10.5516","article-title":"Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines","volume":"161","author":"Wang J","year":"1998","unstructured":"Wang J, Saffold S, Cao X, Krauss J, Chen W. 1998. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516\u20135524.","journal-title":"J Immunol"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008095"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2888"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.024"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0563"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.04.003"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1259\/0007-1285-26-305-234"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2015.10.001"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18309"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri3108"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.11.019"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.08.069"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915174107"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00453"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.2307\/1588867"},{"key":"e_1_3_2_60_2","first-page":"303","article-title":"Newcastle disease virus antibodies in human sera","volume":"73","author":"Charan S","year":"1981","unstructured":"Charan S, Mahajan VM, Agarwal LP. 1981. Newcastle disease virus antibodies in human sera. Indian J Med Res 73:303\u2013307.","journal-title":"Indian J Med Res"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0029-0"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00367-0"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.2174\/156800907780058853"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/718710"},{"key":"e_1_3_2_65_2","unstructured":"Genentech Inc. 10 November 2013 filing date. U.S. patent application 8735553 B1."},{"key":"e_1_3_2_66_2","unstructured":"Genentech Inc. 8 December 2009 filing date. U.S. patent application 8217149 B2."}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01677-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.01677-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:54:47Z","timestamp":1695398087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.01677-19"}},"subtitle":[],"editor":[{"given":"Stacey","family":"Schultz-Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,1,17]]}},"alternative-id":["10.1128\/JVI.01677-19"],"URL":"https:\/\/doi.org\/10.1128\/jvi.01677-19","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"2019-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01677-19"}}